Topical microbicides for the prevention of genital herpes infection
Open Access
- 1 April 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (4) , 420-423
- https://doi.org/10.1093/jac/dki056
Abstract
Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is the most common cause of genital ulcers. Despite increased public awareness and the initiation of efforts to prevent transmission, the prevalence of herpes simplex virus (HSV) type 2 continues to increase. What makes HSV so difficult to control is that most sexual and perinatal transmission occurs during unrecognized or asymptomatic shedding. The impact of genital herpes as a public health threat is amplified because of its epidemiological synergy with HIV/AIDS. Thus, there is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Several candidate microbicides are being advanced to clinical trials based on in vitro activity and animal studies. These include compounds that inactivate virus directly, those that enhance innate immunity, and drugs that block viral binding and entry. A more vigorous evaluation of the safety of these and other candidate topical microbicides in development should include assessment of the impact of repeated application on innate host defences in the genital tract.Keywords
This publication has 24 references indexed in Scilit:
- Persulfated Molecular Umbrellas as Anti-HIV and Anti-HSV AgentsJournal of the American Chemical Society, 2004
- Candidate Topical Microbicides Bind Herpes Simplex Virus Glycoprotein B and Prevent Viral Entry and Cell-to-Cell SpreadAntimicrobial Agents and Chemotherapy, 2004
- θ Defensins Protect Cells from Infection by Herpes Simplex Virus by Inhibiting Viral Adhesion and EntryJournal of Virology, 2004
- Mandelic Acid Condensation Polymer: Novel Candidate Microbicide for Prevention of Human Immunodeficiency Virus and Herpes Simplex Virus EntryJournal of Virology, 2002
- Contribution of Human α-Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral FactorScience, 2002
- Effect of Menstrual Status on Antibacterial Activity and Secretory Leukocyte Protease Inhibitor Production by Human Uterine Epithelial Cells in CultureThe Journal of Infectious Diseases, 2002
- The Molecular Basis of Nonoxynol‐9–Induced Vaginal Inflammation and Its Possible Relevance to Human Immunodeficiency Virus Type 1 TransmissionThe Journal of Infectious Diseases, 2001
- Poly(Sodium 4‐Styrene Sulfonate): An Effective Candidate Topical Antimicrobial for the Prevention of Sexually Transmitted DiseasesThe Journal of Infectious Diseases, 2000
- The Topical Microbicide PRO 2000 Protects against Genital Herpes Infection in a Mouse ModelThe Journal of Infectious Diseases, 1999
- Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.Journal of Clinical Investigation, 1995